Article
Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.
Blood - 16 Sept 2021
Paietta Elisabeth, Roberts Kathryn G, Wang Victoria, Gu Zhaohui, Buck Georgina A N, Pei Deqing, Cheng Cheng, Levine Ross L, Abdel-Wahab Omar, Cheng Zhongshan, Wu Gang, Qu Chunxu, Shi Lei, Pounds Stanley, Willman Cheryl L, Harvey Richard, Racevskis Janis, Barinka Jan, Zhang Yanming, Dewald Gordon W, Ketterling Rhett P, Alejos David, Lazarus Hillard M, Luger Selina M, Foroni Letizia, Patel Bela, Fielding Adele K, Melnick Ari, Marks David I, Moorman Anthony V, Wiernik Peter H, Rowe Jacob M, Tallman Martin S, Goldstone Anthony H, Mullighan Charles G, Litzow Mark R
Abstract excerpt
Genomic classification has improved risk assignment of pediatric, but not adult B-lineage acute lymphoblastic leukemia (B-ALL). The international UKALLXII/ECOG-ACRIN E2993 (#NCT00002514) trial accrued 1229 adolescent/adult patients with BCR-ABL1- B-ALL (aged 14 to 65 years). Although 93% of patients achieved remission, 41% relapsed at a median of 13 months (range, 28 days to 12 years). Five-year overall survival...
Topics
- Adolescent
- Adult
- Female
- Fusion Proteins, bcr-abl
- Gene Rearrangement
- Humans
- Male
- Middle Aged